GSK growing optimistic on HIV but long term challenges remain - analyst
GSK shows increasing confidence in new HIV treatments but longer term challenges remain, according to Jefferies
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
743 stories · page 3 of 8
GSK gets chunky Citi target upgrade after Zantac ruling
Legal precedent also suggests that ongoing state-based litigation is unlikely to result in a material settlement
Hardware & electrical equipment
FIVE at FIVE: GSK soars on court ruling; Pint price hikes; FTSE 100 slides; Microsoft's Nintendo deal; Apple welcomes Taiwan chip investment
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
GSK halts US marketing process for Blenrep after recent disappointing trial data
The news followed the previously announced outcome of the DREAMM-3 phase III trial which failed to meet the FDA requirements, wiping around £1.7bn of the FTSE 100-listed drugs group’s share price
GSK slapped with 'sell' rating over long-term risks
On the plus side for the drug group, analysts said it has time and options, including potentially allocating more cash to "smooth over" the potential 2027 bottleneck
GSK says second-line applications of new cancer drug will be restricted
The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers, remains unchanged
GSK slide wipes off £2.5bn, but for one broker this puts the stock in bargain basement territory
The tumble follows a clinical trial failure for a cancer treatment it developed
GSK loses almost £1.7bn value after drug trial failure
Blenrep was deemed no better than the current standard of care in helping people with late-stage, hard-to-treat multiple myeloma, a type of bone marrow cancer
GSK's new antibiotic a handy add-on, suggests Deutsche Bank
Fluoroquinolones treat a quarter of the 10mln+ annual US UTI cases
GSK to submit urinary infection treatment for approval after trial success
GSK has halted the trials early after an independent assessment concluded it has already met its primary endpoint
GSK results top City forecasts, UBS sees consensus EPS forecasts rising 3%
The broker highlighted strong growth in Vaccines where sales of shingles product, Shingrix, came in 11% ahead of forecast.
GSK lifts guidance again as bumper third quarter results top City forecasts
Strong growth in its Speciality Medicines business and soaring sales of its shingles vaccine, Shingrix, helped the drugmaker report third-quarter sales of £7.83bn comfortably ahead of City forecasts
Wednesday's agenda - Next to iron out latest figures, GSK expecting disappointing results
Previewing Wednesday's news as both GSK and Next release financial updates.
GSK says vaccine for RSV on course to be fast-tracked in Europe
The EMA has also validated GSK subsidiary, ViiV Healthcare’s cabotegravir long-acting injectable HIV preventative
GSK needs to confirm upward curve in next week's update
Its RSV vaccine has been a standout after delivering 83% efficacy in a phase III trial.
GSK reports mixed outcome from meeting with US Food and Drug Administration
An FDA committee voted that the benefits of GSK drug, daprodustat outweighed risks for adult dialysis patients with anaemia of chronic kidney disease (CKD), but not for those not undergoing dialysis
GSK to get boost if Zantac ruling reduces liability fears, reckons Citi
The UK drugs giant is being sued alongside Sanofi, Pfizer and Boehringer Ingelheim
GSK shares trading with 'value disconnect', says broker
This followed the drug giant posting data for its RSV vaccine candidate, demonstrating vaccine efficacy at 83%, with a 94% reduction in severe disease
GSK hails 'truly exceptional' vaccine results
The phase III trial assessed the impact of its RSV jab on the over 60s
GSK board appointment is positive says broker but focus is on weak GBP, Zantac legals
"Investors have picked up on the recent slide of the GBP and the potential translational benefit, given GSK is our only company under coverage that reports in sterling"
GSK poaches Burberry CFO to complete rare all-female executive leadership team
Julie Brown has held several roles at GSK's blue-chip rival AstraZeneca and was a member of former PM Boris Johnson’s business council
GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic
The UK pharma has gained access to a drug ready to move into phase III clinical trials
GSK 'sell' rating removed by Credit Suisse as Zantac liabilities expected to be US$5bn
The overhang from the cancer lawsuits are expected to linger, but the US$12bn wiped off its market cap “is much higher than what we might expect to be GSK’s share of any settlement”
GSK targets cut by Morgan Stanley and Deutsche Bank over potential Zantac liabilities
Analysts said the count of state cases is "likely to snowball if initial outcomes are favourable for plaintiffs"
GSK confirms first Zantac plaintiff drops lawsuit
Joseph Bayer was unable to proceed because of health reasons, said Reuters citing his attorney
FIVE at FIVE: UK drought, big pharma loses, Flutter follows Entain and BT ‘respects’ strikers
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
Big pharma loses US$39bn of market cap over Zantac cancer claims
Value destruction from extended legal battles “can often exceed settlement size by orders of magnitude until absolute clarity emerges", said Barclays, with analysts seeing GSK most exposed in upcoming Zantac trials
GSK to 'vigorously defend' itself against claims stomach acid drug Zantac causes cancer
About 3,000 personal injury cases have been filed in US federal and state courts against GSK
Archive
FTSE 100 closes higher for fourth consecutive week as US stocks extend inflation boost
At the close, the UK blue-chip index was up 34.98 points, or 0.5% at 7,500.89, below the session peak of 7,516.83, but well above the day’s low of 7,464.12
GSK and Haleon given headache by cancer-linked heartburn drug
'Perhaps the key reason for share price weakness might be market worries over lawsuits concerning Zantac'
GSK raises full-year guidance after bumper second quarter; shingles drug the star performer
The drugs giant expects sales to grow by as much as 15% this year
GSK: Investors will be looking for early signs that drugs giant will hit newly issued sales and earnings targets
For 2022, the City has been told to expect sales growth of 5% to 7%, leading to a 12% to 14% increase in operating profits
GSK increases dividend expectations as part of share consolidation
Analysts were also adjusting their forecasts, with Barclays saying many clients are "optimistic with regards to the near-term momentum" but others are in 'wait and see' mode
Five at Five: FTSE 100 rallies, Tech pivot?, Welcome Haleon, Celsius black hole
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
What 'New GSK' will look like after the Haleon spin-off
‘New GSK’ will be focused on four areas: infectious diseases, HIV, oncology and immunology, with analysts seeing stronger growth than continental peer group
GSK begins Haleon spin-off process ahead of Monday's listing
For each GSK share owned investors will get a new share in Haleon, which will start trading on Monday
GSK applies for shingles drug label expansion in Japan
It wants doctors to be able to prescribe Shingrix to at-risk groups over the age of 18, including those with compromised immune systems
Investor views on GSK 'significantly swing towards positive' ahead of Haleon spin-off
Those who still have negative views are cautious about long-term forecasts given "a pipeline that is still somewhat work-in-progress"
GlaxoSmithKline needs to be better in pharma arena, suggests Barclays
Barclays upped its forecasts for GSK’s Respiratory Syncytial Virus vaccine following a 'positive' readout
What investors need to know as GSK and Pfizer spin off Haleon
Some analysts see the valuation well short of the £50bn tabled by Unilever, while others reckon GSK will have divested itself of a major "headache"
GSK seeks approval for respiratory vaccine after trials show 'meaningful efficacy'
GSK said the vaccine showed “statistically significant and clinically meaningful efficacy” and no “unexpected safety concerns” were observed
GSK’s Priorix MMR vaccine gets US FDA approval
"We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases," said Judy Stewart, senior vice president and head of US Vaccines, GSK
GSK says Haleon spin-out expected to list on LSE in July
Consumer health company Haleon’s ordinary shares are expected to be admitted to the London Stock Exchange on 18 July
GlaxoSmithKline bolsters its vaccines R&D pipeline with US$3.3bn swoop for American drug developer
It is acquiring Affinivax Inc, which gives it access to a technology being developed to treat pneumococcal diseases such as pneumonia
GlaxoSmithKline's cervical cancer drug wins Chinese approval
The authorities there have said that Cervarix will be administered in two doses
GSK hikes factory workers pay after union calls out derisory offer
Workers had been offered a 2.75% pay rise, a fall in real terms, even after the company made £8.8bn operating profits last year
GlaxoSmithKline: What's the difference between a 'buy idea' and neutral recommendation?
Yeah, we don't know either. Answers on a postcard please...
GlaxoSmithKline's RSV jab progress prompts broker upgrade
The broker has raised its share price target to 1,850p from 1,700p
Hay fever tablets on low supply, say Boots and Superdrug
Its a tough time for hay fever sufferers and sunflower oil lovers
GlaxoSmithKline shares look at five-year highs as activists go quiet
“The end of the pandemic’s been a good thing for GSK"
GlaxoSmithKline sales bounce higher after Covid treatment boost
The total dividend this year will be cut by 35% following the demerger of its consumer healthcare arm Haleon
Why the world’s largest trio of vaccine makers failed on Covid-19
Despite their jab expertise, GlaxoSmithKline, Merck, and Sanofi were outdone by less recognisable names in the space
GlaxoSmithKline says FDA accepts new drug application for specialist anaemia treatment
Daprodustat has been developed for people also suffering from chronic kidney disease
GlaxoSmithKline boosts oncology product line as it swoops for US drug developer in US$1.9bn deal
Sierra Oncology's lead product has successfully navigated a phase III clinical trial
GlaxoSmithKline workers to vote on strike over 2.75% pay offer
Offers on the table amount to a pay cut in real terms, with the latest retail price inflation reaching 7.8% earlier this year
Hermes changes name to Evri, introduces employee pensions
In recent times, Aberdeen Standard Life transformed to Abrdn, Weight Watchers turned into Wellness and Wellbeing and Facebook changed its name to Meta.
GlaxoSmithKline devalued as it moves toward Haleon demerger - broker
Haleon demerger will refocus investors while positive data on RSV vaccine could accelerate closing of devaluation gap, says Berenberg
GlaxoSmithKline has European marketing application accepted for kidney disease drug
Company said marketing permission is biggest milestone for HIF-PHI daprodustat since Japanese approval
GlaxoSmithKline gets first Covid-19 vaccine approved
Canada has approved the jab, which was developed in collaboration with Medicago
GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval
Results from the Phase III trials were expected to be released last year
GlaxoSmithKline says demerger of consumer healthcare company Haleon on track for mid-2022
“Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders," GSK CEO Emma Walmsley
GlaxoSmithKline goes with Haleon as new name of its Consumer Healthcare division
On the plus side, the name does not have any seemingly raNdOm caPitAl letters in it
GlaxoSmithKline hits the pause button on RSV vaccination trial
Enrolment was halted on the advice of an independent data monitoring committee
GlaxoSmithKline investors would be glad of some positivity, but will they find it on Wednesday?
Glaxo, Barratt and Dunelm are among the notable names in the diary for Wednesday.
Archive
FTSE 100 closes higher with help from oil giants, banks and miners
The oil price is down but Shell and BP - the latter ahead of results - are on the rise
GlaxoSmithKline JV to receive US$1.25bn after HIV case settlement
It brings to an end a long-running legal wrangle with US giant Gilead Sciences
GlaxoSmithKline names Tony Wood chief scientific officer to succeed Hal Barron
Barron has been appointed as chief executive officer of the new US biotech company Altos Labs
GlaxoSmithKline shares rise after it rejects Unilever bid for its consumer healthcare division
GSK's board is under pressure from activist shareholders to sell the Consumer Healthcare business but it believes the £50bn Unilever bid undervalues the company.
Archive
FTSE 100 closes above 7,600 points on M&A boost
The Footsie has again risen above 7,600 but this time with a bit more authority
GlaxoSmithKline names ex-Tesco chief Sir Dave Lewis to chair consumer healthcare spin-off
The demerger of the consumer healthcare business will take place in mid-2022 and the new company will list on the London Stock Exchange
GlaxoSmithKline/Sanofi COVID-19 vaccine effective as booster shot, trial shows
"These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received"
COVID drug co-developed by GlaxoSmithKline effective against omicron variant, second preclinical study shows
"Sotrovimab is the first monoclonal antibody to report preclinical data demonstrating activity against all tested SARS-CoV-2 variants of concern and interest to date, including omicron, as well as the still prevalent and highly contagious d
GlaxoSmithKline COVID-19 drug effective against Omicron variant, data shows
Sotrovimab was deliberately designed with a mutating virus in mind
GlaxoSmithKline's appeal to become much clearer in 2022 says broker
Berenberg price target is 1,630p and 'buy' its investment view
GlaxoSmithKline ups earnings forecast as sales momentum builds
Earnings in 2021 are now expected to decline by between 2% to 4%, compared to a predicted fall of mid to high-single-digits
FTSE 100 closes in the red after Chancellor reveals Budget
Wetherspoons and Mitchells & Butlers were among the best risers
Archive
It’s UK Budget time of the year again
GlaxoSmithKline is scheduled to publish a quarterly update, however it may only get attention from activist investors Elliott Management and Bluebell Capital Partners
GlaxoSmithKline boss Emma Walmsley to remain key focus for activist investors on quarterly results
Elliott Management and Bluebell Capital Partners will closely watch any statement from the chief executive
GlaxoSmithKline consumer arm attracting private equity interest - report
Activist Elliott has already called for the consumer unit to be sold
GlaxoSmithKline calls time on iconic London HQ as split moves ahead
GSK House was opened by Tony Blair in 2002 after the merger of SmithKline Beecham and GlaxoWellcome.
UK launches biggest ever flu jab campaign amid fear of surge in deaths
Flu deaths could reach 60,000 this winter, a report from the Academy of Medical Sciences found
Archive
FTSE 100 makes progress on ESG front but female leadership still too low
Only eight women are chief executives and 15 chief financial officers or finance directors at the biggest companies listed in London
GSK gets WHO recommendation for roll-out of malaria vaccine
RTS,S vaccine, in combination with seasonal administration of antimalarials, lowers clinical episodes of malaria, hospital admissions with severe malaria and deaths by around 70%, the company said.
GlaxoSmithKline strengthens HIV pipeline with new Japanese deal
In human studies are expected of the new medicine are expected to start in 2023
GlaxoSmithKline boss Walmsley faces second activist investor demanding change
Both activists are pushing for the drug giant to launch a new process to find a boss for the drug and vaccine business once the consumer health arm is spun off
GlaxoSmithKline shares fall, but is now the time to start buying? Here's what one Wall Street research house reckons
Jefferies International is a fan of the drug developer
GlaxoSmithKline to test new Covid vaccine against AstraZeneca jab
This study will be one of the first global Phase 3 trials to compare two different Covid-19 vaccine candidates
GlaxoSmithKline investors set for deep value if they stay patient
The European broker sees around 8% upside to for the pharma giant.
AstraZeneca boss urges rival at GlaxoSmithKline to stick to her guns
GSK is one of several companies - most of them headed by women, coincidentally (?) - to come under pressure from activist investors
GlaxoSmithKline improvement likely in 2022 according to UBS
The pharma needs to show some earnings growth rather than just be seen as a value stock
GlaxoSmithKline maintains guidance but Shingrix still sluggish
Sales of Shingles vaccine Shingrix are recovering more slowly than expected
GSK plans to create giant UK biotech cluster
The site is already the UK’s largest cell and gene therapy cluster
GlaxoSmithKline: This is what one leading Wall Street bank thinks of the CEO's plans
Morgan Stanley has provided little encouragement to the drug giant in its latest note
GlaxoSmithKline backs under-fire CEO and adds Parkinson's and Alzheimer's drugs
A deal struck with Alector will see the US-based company receive US$700mln in upfront payments and up to US$1.5bn in milestones